User:Saksham Aggarwal23/Sample page

Coronavirus disease 2019 (COVID-19) Coronavirus disease 2019 (COVID-19), also known as COVID and the coronavirus, is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The first known case was identified in Wuhan, China, in December 2019.[7] The disease has since spread worldwide, leading to an ongoing pandemic.[8]

Symptoms of COVID-19 are variable, but often include fever,[9] cough, headache,[10] fatigue, breathing difficulties, and loss of smell and taste.[11][12][13] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[14] Of those people who develop symptoms noticeable enough to be classed as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[15] Older people are at a higher risk of developing severe symptoms. Some people continue to experience a range of effects (long COVID) for months after recovery, and damage to organs has been observed.[16] Multi-year studies are underway to further investigate the long-term effects of the disease.[16]

COVID-19 transmits when people breathe in air contaminated by droplets and small airborne particles containing the virus. The risk of breathing these in is highest when people are in close proximity, but they can be inhaled over longer distances, particularly indoors. Transmission can also occur if splashed or sprayed with contaminated fluids in the eyes, nose or mouth, and, rarely, via contaminated surfaces. People remain contagious for up to 20 days, and can spread the virus even if they do not develop symptoms.[17][18]

Several testing methods have been developed to diagnose the disease. The standard diagnostic method is by detection of the virus' nucleic acid by real-time reverse transcription polymerase chain reaction (rRT-PCR), transcription-mediated amplification (TMA), or by reverse transcription loop-mediated isothermal amplification (RT-LAMP) from a nasopharyngeal swab.

Several COVID-19 vaccines have been approved and distributed in various countries, which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. The use of face masks or coverings has been recommended in public settings to minimize the risk of transmissions. While work is underway to develop drugs that inhibit the virus, the primary treatment is symptomatic. Management involves the treatment of symptoms, supportive care, isolation, and experimental measures. Symptoms of COVID-19 are variable, ranging from mild symptoms to severe illness.[33][34] Common symptoms include headache, loss of smell and taste, nasal congestion and runny nose, cough, muscle pain, sore throat, fever, diarrhea, and breathing difficulties.[35] People with the same infection may have different symptoms, and their symptoms may change over time. Three common clusters of symptoms have been identified: one respiratory symptom cluster with cough, sputum, shortness of breath, and fever; a musculoskeletal symptom cluster with muscle and joint pain, headache, and fatigue; a cluster of digestive symptoms with abdominal pain, vomiting, and diarrhea.[35] In people without prior ear, nose, and throat disorders, loss of taste combined with loss of smell is associated with COVID-19.[36]

Of people who show symptoms, 81% develop only mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging) and 5% of patients suffer critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[37] At least a third of the people who are infected with the virus do not develop noticeable symptoms at any point in time.[38][39] These asymptomatic carriers tend not to get tested and can spread the disease.[39][40][41][42] Other infected people will develop symptoms later, called "pre-symptomatic", or have very mild symptoms and can also spread the virus.[42]

As is common with infections, there is a delay between the moment a person first becomes infected and the appearance of the first symptoms. The median delay for COVID-19 is four to five days.[43] Most symptomatic people experience symptoms within two to seven days after exposure, and almost all will experience at least one symptom within 12 days.[43][44]

Most people recover from the acute phase of the disease. However, some people – over half of a cohort of home-isolated young patients[45][46] – continue to experience a range of effects, such as fatigue, for months after recovery, a condition called long COVID; long-term damage to organs has been observed. Multi-year studies are underway to further investigate the long-term effects of the disease.[47] Transmission Main article: Transmission of COVID-19

Transmission of COVID-19

The respiratory route of spread of COVID-19, encompassing larger droplets and aerosols. The disease is mainly transmitted via the respiratory route when people inhale droplets and small airborne particles (that form an aerosol) that infected people breath out as they breathe, talk, cough, sneeze, or sing.[49][50][51] Infected people are more likely to transmit COVID-19 when they are physically close. However, infection can occur over longer distances, particularly indoors.[49][52]

Infectivity begins as early as three days before symptoms appear, and people are most infectious just prior to and during the onset of symptoms.[53] It declines after the first week, but infected people remain contagious for up to 20 days. People can spread the disease even if they are asymptomatic.[54][55][53]

Infectious particles range in size from aerosols that remain suspended in the air for long periods of time to larger droplets that remain airborne or fall to the ground.[56][57] Various groups utilise terms such as "airborne" and "droplet" both in technical and general ways, leading to confusion around terminology.[58] Additionally, COVID-19 research has redefined the traditional understanding of how respiratory viruses are transmitted.[57][59] The largest droplets of respiratory fluid do not travel far, and can be inhaled or land on mucous membranes on the eyes, nose, or mouth to infect.[56] Aerosols are highest in concentration when people are in close proximity, which leads to easier viral transmission when people are physically close,[56][57][59] but airborne transmission can occur at longer distances, mainly in locations that are poorly ventilated;[56] in those conditions small particles can remain suspended in the air for minutes to hours.[56]

The number of people generally infected by one infected person varies;[60] as only 10 to 20% of people are responsible for the disease's spread.[61] It often spreads in clusters, where infections can be traced back to an index case or geographical location.[62] Often in these instances, superspreading events occur, where many people are infected by one person.[60]

China and Covid relations Biological weapons which are not possessed by any economically developing countries but by are possessed by one of the world’s superpower China, Covid-19 is the most dangerous but smallest weapon and is also a potential bio weapon. When the treaties for eradication of weapons of mass destruction from countries were made, we also had to disarm weapons of China. China a well-developed nation has made Covid-19 so as to multiply its economy and to market to resell the masks and sanitizers received as a donation when Covid first stuck Wuhan. The international committee was in astonishment that the use of weapons of mass destruction are now being used for multiplying a nation's economy and also to brutally kill people. China is trying to push the rest of the world down by using inappropriate means and by doing this China won't be able to succour.

Virology Main article: Severe acute respiratory syndrome coronavirus 2

Illustration of SARSr-CoV virion Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel severe acute respiratory syndrome coronavirus. It was first isolated from three people with pneumonia connected to the cluster of acute respiratory illness cases in Wuhan.[63] All structural features of the novel SARS-CoV-2 virus particle occur in related coronaviruses in nature.[64]

Outside the human body, the virus is destroyed by household soap, which bursts its protective bubble.[65]

SARS-CoV-2 is closely related to the original SARS-CoV.[66] It is thought to have an animal (zoonotic) origin. Genetic analysis has revealed that the coronavirus genetically clusters with the genus Betacoronavirus, in subgenus Sarbecovirus (lineage B) together with two bat-derived strains. It is 96% identical at the whole genome level to other bat coronavirus samples (BatCov RaTG13).[67][68] The structural proteins of SARS-CoV-2 include membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and the spike protein (S). The M protein of SARS-CoV-2 is about 98% similar to the M protein of bat SARS-CoV, maintains around 98% homology with pangolin SARS-CoV, and has 90% homology with the M protein of SARS-CoV; whereas, the similarity is only around 38% with the M protein of MERS-CoV. The structure of the M protein resembles the sugar transporter SemiSWEET.[69]

Cardiovascular system The virus can cause acute myocardial injury and chronic damage to the cardiovascular system.[89] An acute cardiac injury was found in 12% of infected people admitted to the hospital in Wuhan, China,[90] and is more frequent in severe disease.[91] Rates of cardiovascular symptoms are high, owing to the systemic inflammatory response and immune system disorders during disease progression, but acute myocardial injuries may also be related to ACE2 receptors in the heart.[89] ACE2 receptors are highly expressed in the heart and are involved in heart function.[89][92] A high incidence of thrombosis and venous thromboembolism have been found in people transferred to Intensive care units (ICU) with COVID-19 infections, and may be related to poor prognosis.[93] Blood vessel dysfunction and clot formation (as suggested by high D-dimer levels caused by blood clots) are thought to play a significant role in mortality, incidences of clots leading to pulmonary embolisms, and ischaemic events within the brain have been noted as complications leading to death in people infected with SARS-CoV-2. Infection appears to set off a chain of vasoconstrictive responses within the body, constriction of blood vessels within the pulmonary circulation has also been posited as a mechanism in which oxygenation decreases alongside the presentation of viral pneumonia.[94] Furthermore, microvascular (arterioles and capillaries) blood vessel damage has been reported in a small number of tissue samples of the brains – without detected SARS-CoV-2 – and the olfactory bulbs from those who have died from COVID-19.[95][96][97] COVID-19 was also found to cause substantial – including morphological and mechanical – changes to blood cells – such as increased sizes – sometimes persisting for months after hospital discharge.[98][99]

Immunopathology

Key components of the adaptive immune response to SARS-CoV-2 Although SARS-CoV-2 has a tropism for ACE2-expressing epithelial cells of the respiratory tract, people with severe COVID-19 have symptoms of systemic hyperinflammation. Clinical laboratory findings of elevated IL‑2, IL‑7, IL‑6, granulocyte-macrophage colony-stimulating factor (GM‑CSF), interferon gamma-induced protein 10 (IP‑10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory protein 1‑alpha (MIP‑1‑alpha), and tumour necrosis factor (TNF‑α) indicative of cytokine release syndrome (CRS) suggest an underlying immunopathology.[90]

Additionally, people with COVID-19 and acute respiratory distress syndrome (ARDS) have classical serum biomarkers of CRS, including elevated C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and ferritin.[102]

Systemic inflammation results in vasodilation, allowing inflammatory lymphocytic and monocytic infiltration of the lung and the heart. In particular, pathogenic GM-CSF-secreting T cells were shown to correlate with the recruitment of inflammatory IL-6-secreting monocytes and severe lung pathology in people with COVID-19.[103] Lymphocytic infiltrates have also been reported at autopsy.[101]

Viral and host factors

Viral testing Main article: COVID-19 testing

Demonstration of a nasopharyngeal swab for COVID-19 testing The standard methods of testing for presence of SARS-CoV-2 are nucleic acid tests,[114][117] which detects the presence of viral RNA fragments.[118] As these tests detect RNA but not infectious virus, its "ability to determine duration of infectivity of patients is limited."[119] The test is typically done on respiratory samples obtained by a nasopharyngeal swab; however, a nasal swab or sputum sample may also be used.[120][121] Results are generally available within hours.[114] The WHO has published several testing protocols for the disease.[122]

Several laboratories and companies have developed serological tests, which detect antibodies produced by the body in response to infection. Several have been evaluated by Public Health England and approved for use in the UK.[123]

The University of Oxford's CEBM has pointed to mounting evidence[124][125] that "a good proportion of 'new' mild cases and people re-testing positives after quarantine or discharge from hospital are not infectious, but are simply clearing harmless virus particles which their immune system has efficiently dealt with" and have called for "an international effort to standardize and periodically calibrate testing"[126] On 7 September, the UK government issued "guidance for procedures to be implemented in laboratories to provide assurance of positive SARS-CoV-2 RNA results during periods of low prevalence, when there is a reduction in the predictive value of positive test results".[127]